Molecular Mechanisms and Biomarkers in Osteoporosis

Osteoporosis arises from an imbalance between bone formation and resorption, driven by complex molecular networks governing osteoblast and osteoclast activity. Key signalling pathways include RANK–RANKL–OPG, Wnt/β-catenin and MAPK cascades, which regulate differentiation, survival and function of bone-modelling cells. Inflammatory cytokines such as interleukins and tumour necrosis factor contribute to osteoclastogenesis, while osteoblast maturation depends on transcription factors Runx2 and osterix. Advances in circulating biomarker discovery have identified proteins, lipids and microRNAs that reflect bone turnover and fracture risk more sensitively than bone mineral density alone. In parallel, extracellular matrix constituents, including collagen domains and non-collagenous proteins, are being catalogued to reveal conserved regulators of mineral deposition. Integrative omics approaches—combining proteomics, transcriptomics and network analysis—are uncovering novel gene modules and post-translational modifications implicated in accelerated bone ageing and offering routes to personalised risk assessment and targeted therapies.

Research from Nature Portfolio

A novel computational framework has been developed to correct crosstalk effects in pathway analysis of monocyte gene expression, revealing independent signalling modules linked to bone mineral density variation. By adjusting for overlapping genes, researchers reinstated the significance of MAPK and mitochondrial pathways in osteoclast differentiation, offering a refined map of functional networks. This approach provides a blueprint for high-resolution interrogation of dysregulated signalling in osteoporosis and highlights therapeutically actionable nodes within complex gene–pathway interactions.

Molecular Mechanisms and Biomarkers in Osteoporosis publication trend

The graph below shows the total number of articles in molecular mechanisms and biomarkers in osteoporosis across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoblast: A bone-forming cell that synthesises matrix proteins and initiates mineralisation.

Osteoclast: A multinucleated cell responsible for bone resorption, derived from monocyte/macrophage precursors.

Bone Mineral Density (BMD): A quantitative measure of mineral content in bone, used to diagnose osteoporosis and assess fracture risk.

Biomarker: A molecule or parameter that objectively indicates physiological or pathological processes or responses to therapy.

Extracellular Matrix (ECM): The network of structural and regulatory proteins secreted by cells that provides mechanical support and signalling cues in tissues.

Pathway Crosstalk: Overlapping gene or protein components among signalling pathways that can lead to confounded interpretation in network analyses.

Proximity Extension Assay (PEA): A high-sensitivity immunoassay technique employing DNA-tagged antibodies to quantify multiple proteins simultaneously.

Ferroptosis: An iron-dependent form of regulated cell death associated with lipid peroxidation, recently implicated in postmenopausal bone loss.

References

1. Phylobone: a comprehensive database of bone extracellular matrix proteins in human and model organisms. Bone Research (2023).
2. Proteome‐wide profiling reveals dysregulated molecular features and accelerated aging in osteoporosis: A 9.8‐year prospective study. Aging Cell (2023).
3. Effect of immunology biomarkers associated with hip fracture and fracture risk in older adults. Immunity & Ageing (2023).
4. A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research. Scientific Reports (2018).
5. Identification of ferroptosis-associated biomarkers for the potential diagnosis and treatment of postmenopausal osteoporosis. Frontiers in Endocrinology (2022).